Trial Profile
Observation of Treatment Patterns With Lucentis and Real Life Ophthalmic Monitoring, Including Optional OCT in Approved Indications
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Mar 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Branch retinal vein occlusion; Choroidal neovascularisation; Degenerative myopia; Diabetic macular oedema; Retinal oedema; Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms OCEAN
- Sponsors Novartis
- 01 Dec 2018 Results published in the Diabetes Therapy
- 28 Feb 2017 Status changed from active, no longer recruiting to completed.
- 27 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.